SG139556A1 - Method for inhibiting bone resorption - Google Patents
Method for inhibiting bone resorptionInfo
- Publication number
- SG139556A1 SG139556A1 SG200603406-0A SG2006034060A SG139556A1 SG 139556 A1 SG139556 A1 SG 139556A1 SG 2006034060 A SG2006034060 A SG 2006034060A SG 139556 A1 SG139556 A1 SG 139556A1
- Authority
- SG
- Singapore
- Prior art keywords
- bone resorption
- inhibiting bone
- disclosed
- group
- methods
- Prior art date
Links
- 208000006386 Bone Resorption Diseases 0.000 title abstract 3
- 230000024279 bone resorption Effects 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- -1 etridronate Chemical compound 0.000 abstract 3
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 abstract 1
- 229940122361 Bisphosphonate Drugs 0.000 abstract 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 abstract 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 150000004663 bisphosphonates Chemical class 0.000 abstract 1
- 229960001380 cimetidine Drugs 0.000 abstract 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 abstract 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 abstract 1
- 229960002286 clodronic acid Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229960001596 famotidine Drugs 0.000 abstract 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 abstract 1
- 229940015872 ibandronate Drugs 0.000 abstract 1
- LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 abstract 1
- 229950006971 incadronic acid Drugs 0.000 abstract 1
- 229960003174 lansoprazole Drugs 0.000 abstract 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 abstract 1
- 229960004872 nizatidine Drugs 0.000 abstract 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 abstract 1
- 229960000381 omeprazole Drugs 0.000 abstract 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 abstract 1
- 229940046231 pamidronate Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940126409 proton pump inhibitor Drugs 0.000 abstract 1
- 239000000612 proton pump inhibitor Substances 0.000 abstract 1
- 229940089617 risedronate Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 229940019375 tiludronate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Unknown Constitution (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Saccharide Compounds (AREA)
- Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
- Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
- Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5335197P | 1997-07-22 | 1997-07-22 | |
| US5353597P | 1997-07-23 | 1997-07-23 | |
| GBGB9717590.5A GB9717590D0 (en) | 1997-08-20 | 1997-08-20 | Oral method for treating or preventing abnormal bone resorption |
| GBGB9717850.3A GB9717850D0 (en) | 1997-08-22 | 1997-08-22 | Oral method for treating or preventing abnormal bone resorption |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG139556A1 true SG139556A1 (en) | 2008-02-29 |
Family
ID=27451690
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG200603406-0A SG139556A1 (en) | 1997-07-22 | 1998-07-17 | Method for inhibiting bone resorption |
| SG200107221A SG109478A1 (en) | 1997-07-22 | 1998-07-17 | Method for inhibiting bone resorption |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG200107221A SG109478A1 (en) | 1997-07-22 | 1998-07-17 | Method for inhibiting bone resorption |
Country Status (31)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1147773B1 (en) * | 1998-12-25 | 2004-04-07 | Yamanouchi Pharmaceutical Co. Ltd. | Medicinal compositions for treating osseous lesion in multiple myeloma |
| PL351674A1 (en) * | 1999-05-21 | 2003-05-19 | Novartis Ag | Use of bisphosphonic acids for treating angiogenesis |
| US6670343B1 (en) * | 1999-07-19 | 2003-12-30 | Toray Industries, Inc. | Drugs for periodontal disease |
| AU2270101A (en) * | 1999-12-20 | 2001-07-03 | Merck & Co., Inc. | Pharmaceutical kit |
| WO2001046040A1 (en) | 1999-12-20 | 2001-06-28 | Merck & Co., Inc. | Blister package for pharmaceutical treatment card |
| CN1446093A (zh) * | 2000-04-07 | 2003-10-01 | 得克萨斯系统大学董事会 | 两性离子型磷脂和双膦酸酯的独特组合物及其作为降低肠胃毒性的双膦酸酯释放系统的应用 |
| DK1591122T3 (da) * | 2000-06-20 | 2013-02-25 | Novartis Ag | Fremgangsmåde til indgivelse af bisphosphonater |
| NZ523086A (en) | 2000-06-20 | 2007-07-27 | Novartis Ag | Method of administering bisphosphonates |
| US6638920B2 (en) * | 2000-07-21 | 2003-10-28 | Merck & Co., Inc. | Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses |
| SE0101379D0 (sv) | 2001-04-18 | 2001-04-18 | Diabact Ab | Komposition som hämmar utsöndring av magsyra |
| EP1392325B1 (en) * | 2001-05-02 | 2006-06-21 | Novartis AG | Method of administration of bisphosphonates by inhalation in the treatment or prevention of bone resorption and osteoporosis |
| KR20150053811A (ko) * | 2002-05-10 | 2015-05-18 | 에프. 호프만-라 로슈 아게 | 골다공증 치료 및 예방용 비스포스폰산 |
| SE0203065D0 (sv) | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
| CN1852719A (zh) * | 2003-09-19 | 2006-10-25 | 辉瑞产品公司 | 包括2－亚烷基－19－去甲－维生素d衍生物和二膦酸盐的组合的药物组合物和方法 |
| WO2005072747A1 (ja) * | 2004-02-02 | 2005-08-11 | Ono Pharmaceutical Co., Ltd. | 骨吸収抑制剤 |
| NZ567200A (en) * | 2005-09-16 | 2010-08-27 | Selamine Ltd | Bisphosphonate formulation |
| CN103140220A (zh) * | 2010-12-06 | 2013-06-05 | 给药技术公司 | 具有快速溶解特性的稳定的泡腾双磷酸盐制剂 |
| CN106924257B (zh) * | 2017-03-14 | 2019-11-19 | 湖南赛隆药业有限公司 | 质子泵抑制剂和抗骨质疏松药的复合物及其用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989004178A1 (en) * | 1987-11-13 | 1989-05-18 | Aktiebolaget Hässle | New therapeutical use of h2-receptor-blocking compounds |
| US5364616A (en) * | 1992-04-15 | 1994-11-15 | The Procter & Gamble Company | Use of H-2 antagonists for treatment of gingivitis |
| US5393531A (en) * | 1991-07-01 | 1995-02-28 | Gerhard; Gergely | Process for the preparation of a pharmaceutical formulation containing at least two different active substances and use of such a formulation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL84731A0 (en) * | 1986-12-19 | 1988-05-31 | Norwich Eaton Pharma | Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them |
| WO1993009785A1 (en) * | 1991-11-22 | 1993-05-27 | Procter & Gamble Pharmaceuticals, Inc. | Risedronate delayed-release compositions |
| US5270365A (en) * | 1991-12-17 | 1993-12-14 | Merck & Co., Inc. | Prevention and treatment of periodontal disease with alendronate |
| DK0648120T3 (da) * | 1992-06-30 | 1998-01-19 | Procter & Gamble Pharma | Anvendelse af phosphonater til behandling af osteoporose |
| US5431920A (en) * | 1993-09-21 | 1995-07-11 | Merck Frosst, Canada, Inc. | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents |
| US5646134A (en) * | 1994-04-21 | 1997-07-08 | Merck & Co., Inc. | Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices |
| JPH11506750A (ja) * | 1995-06-06 | 1999-06-15 | メルク エンド カンパニー インコーポレーテッド | 慢性関節リウマチに係わる骨欠損に対するビスホスホネート療法 |
| JP2000511178A (ja) * | 1996-05-17 | 2000-08-29 | メルク エンド カンパニー インコーポレーテッド | 発泡性ビスホスホネート製剤 |
-
1998
- 1998-07-17 DE DE200712000063 patent/DE122007000063I1/de active Pending
- 1998-07-17 PL PL98338635A patent/PL195272B1/pl unknown
- 1998-07-17 IL IL13353598A patent/IL133535A0/xx unknown
- 1998-07-17 ES ES98935752T patent/ES2164447T3/es not_active Expired - Lifetime
- 1998-07-17 DE DE69837450T patent/DE69837450T2/de not_active Expired - Lifetime
- 1998-07-17 ID IDW20000114A patent/ID24096A/id unknown
- 1998-07-17 EE EEP200000040A patent/EE05603B1/xx unknown
- 1998-07-17 ES ES01201910T patent/ES2253136T1/es active Pending
- 1998-07-17 PT PT98935752T patent/PT998292E/pt unknown
- 1998-07-17 SI SI9830086T patent/SI0998292T1/xx unknown
- 1998-07-17 TR TR2000/00145T patent/TR200000145T2/xx unknown
- 1998-07-17 KR KR1020027013594A patent/KR20030097610A/ko not_active Ceased
- 1998-07-17 AT AT98935752T patent/ATE209037T1/de active
- 1998-07-17 KR KR1020027013595A patent/KR20030097611A/ko not_active Ceased
- 1998-07-17 SK SK93-2000A patent/SK932000A3/sk not_active Application Discontinuation
- 1998-07-17 CN CNB2004100557350A patent/CN1299689C/zh not_active Expired - Lifetime
- 1998-07-17 EA EA200000151A patent/EA004544B2/ru not_active IP Right Cessation
- 1998-07-17 EP EP01201910A patent/EP1132088A3/en not_active Ceased
- 1998-07-17 BR BR9810779-8A patent/BR9810779A/pt not_active Application Discontinuation
- 1998-07-17 WO PCT/US1998/014796 patent/WO1999004773A2/en not_active Ceased
- 1998-07-17 EP EP01201912A patent/EP1175903A3/en not_active Ceased
- 1998-07-17 EP EP01201911A patent/EP1151752A3/en not_active Ceased
- 1998-07-17 AT AT01201913T patent/ATE357921T1/de active
- 1998-07-17 DK DK98935752T patent/DK0998292T3/da active
- 1998-07-17 CN CNB988074737A patent/CN1166365C/zh not_active Ceased
- 1998-07-17 DE DE01201913T patent/DE01201913T1/de active Pending
- 1998-07-17 DE DE01201911T patent/DE01201911T1/de active Pending
- 1998-07-17 DK DK01201913T patent/DK1175904T3/da active
- 1998-07-17 SG SG200603406-0A patent/SG139556A1/en unknown
- 1998-07-17 SG SG200107221A patent/SG109478A1/en unknown
- 1998-07-17 NZ NZ501807A patent/NZ501807A/en not_active IP Right Cessation
- 1998-07-17 CN CNA2004100557346A patent/CN1602879A/zh active Pending
- 1998-07-17 DE DE69803291T patent/DE69803291T2/de not_active Revoked
- 1998-07-17 CA CA002294595A patent/CA2294595C/en not_active Expired - Fee Related
- 1998-07-17 DE DE1998603291 patent/DE122006000009I1/de active Pending
- 1998-07-17 PT PT01201913T patent/PT1175904E/pt unknown
- 1998-07-17 AU AU84936/98A patent/AU8493698A/en not_active Abandoned
- 1998-07-17 JP JP50991499A patent/JP3479780B2/ja not_active Expired - Lifetime
- 1998-07-17 ES ES01201913T patent/ES2269014T3/es not_active Expired - Lifetime
- 1998-07-17 EP EP01201913A patent/EP1175904B8/en not_active Revoked
- 1998-07-17 KR KR1020007000680A patent/KR100391732B1/ko not_active Expired - Fee Related
- 1998-07-17 EP EP98935752A patent/EP0998292B1/en not_active Revoked
-
1999
- 1999-12-21 IS IS5315A patent/IS5315A/is unknown
-
2000
- 2000-01-17 UY UY25950A patent/UY25950A1/es not_active Application Discontinuation
- 2000-01-18 BG BG104093A patent/BG66282B1/bg unknown
- 2000-01-21 NO NO20000323A patent/NO20000323L/no unknown
-
2002
- 2002-03-04 HK HK02101656.1A patent/HK1042230A1/en unknown
- 2002-03-12 HK HK02101869.4A patent/HK1042232A1/en unknown
- 2002-03-16 HK HK02102042.2A patent/HK1040494A1/en unknown
- 2002-03-16 HK HK02102043.1A patent/HK1040495A1/en unknown
-
2003
- 2003-03-10 JP JP2003063378A patent/JP2005068010A/ja active Pending
-
2004
- 2004-04-21 IS IS7231A patent/IS7231A/is unknown
- 2004-04-21 IS IS7230A patent/IS7230A/is unknown
-
2006
- 2006-02-07 NL NL300223C patent/NL300223I1/nl unknown
- 2006-02-15 LU LU91222C patent/LU91222I2/fr unknown
-
2007
- 2007-03-29 CY CY20071100442T patent/CY1107535T1/el unknown
- 2007-09-12 LU LU91364C patent/LU91364I2/fr unknown
- 2007-09-13 NL NL300292C patent/NL300292I1/nl unknown
- 2007-09-20 CY CY2007022C patent/CY2007022I1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989004178A1 (en) * | 1987-11-13 | 1989-05-18 | Aktiebolaget Hässle | New therapeutical use of h2-receptor-blocking compounds |
| US5393531A (en) * | 1991-07-01 | 1995-02-28 | Gerhard; Gergely | Process for the preparation of a pharmaceutical formulation containing at least two different active substances and use of such a formulation |
| US5364616A (en) * | 1992-04-15 | 1994-11-15 | The Procter & Gamble Company | Use of H-2 antagonists for treatment of gingivitis |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL300292I1 (nl) | Werkwijze voor het inhibiteren van botresorptie | |
| HRP20020594B1 (en) | Pharmaceutical parenteral composition containing a biphosphonate | |
| NZ272608A (en) | Inhibiting bone loss by administering a bisphosphonate and a second compound selected from various compounds, including 2-phenyl-3-aroylbenzothienes; bisphosphonate combination salts | |
| WO2001097788A3 (en) | Method of administering bisphosphonates | |
| NZ527157A (en) | Compositions for delivering bisphosphonates | |
| JP2002529490A5 (cg-RX-API-DMAC7.html) | ||
| NZ545804A (en) | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate | |
| YU1800A (sh) | Upotreba bisfosfonata za proizvodnju leka za inhibiranje resorpcije kostiju | |
| PE120399A1 (es) | Composiciones que inhiben la resorcion osea |